Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Working Capital Changes (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Other Working Capital Changes data on record, last reported at -$64000.0 in Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 107.65% year-over-year to -$64000.0; the TTM value through Sep 2025 reached -$1.6 million, down 839.34%, while the annual FY2024 figure was -$252000.0, 3250.0% down from the prior year.
  • Other Working Capital Changes reached -$64000.0 in Q3 2025 per CRVS's latest filing, up from -$1.1 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $837000.0 in Q3 2024 and bottomed at -$1.8 million in Q4 2022.
  • Average Other Working Capital Changes over 4 years is -$162333.3, with a median of -$118000.0 recorded in 2023.
  • The widest YoY moves for Other Working Capital Changes: up 230.37% in 2024, down 964.58% in 2024.
  • A 4-year view of Other Working Capital Changes shows it stood at -$1.8 million in 2022, then skyrocketed by 102.63% to $48000.0 in 2023, then plummeted by 964.58% to -$415000.0 in 2024, then surged by 84.58% to -$64000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$64000.0 in Q3 2025, -$1.1 million in Q2 2025, and $31000.0 in Q1 2025.